Bioinformatic Profiling Identifies a Fatty Acid Metabolism-Related Gene Risk Signature for Malignancy, Prognosis, and Immune Phenotype of Glioma
Table 2
Univariate and multivariate Cox regression analysis of the clinical features and risk score for overall survival in CGGA and TCGA datasets.
Univariate analysis
Multivariate analysis
Variables
HR
95% CI
p value
HR
95% CI
p value
Training set CGGA RNA-seq cohort ()
Age
1.038
1.023~1.054
<0.0001
0.9992
0.9832~1.0155
0.9239
Gender
1.1701
0.8291~1.651
0.371
1.2047
0.8257~1.7576
0.3340
Grade
0.1697
0.1167~0.2469
<0.0001
0.5155
0.3203~0.8295
0.0063
IDH status
4.285
2.971~6.181
<0.0001
0.9195
0.5404~1.5643
0.7568
Chemotherapy
1.233
0.8736~1.74
0.234
0.9005
0.6223~1.3030
0.5782
Radiotherapy
0.4056
0.2839~0.5795
<0.0001
0.3655
0.2471~0.5406
<0.0001
Risk score
5.118
3.913~6.695
<0.0001
4.0044
2.7634~5.8028
<0.0001
Validation set TCGA RNA-seq cohort ()
Age
1.067
1.057~1.077
<0.0001
1.0283
1.0142~1.0425
<0.0001
Gender
1.236
0.9566~1.596
0.105
1.3371
0.9729~1.8377
0.0734
Grade
0.11
0.08377~0.1444
<0.0001
0.6047
0.4021~0.9095
0.0157
IDH status
9.775
7.365~12.97
<0.0001
2.7861
1.7093~4.5413
<0.0001
Chemotherapy
0.4079
0.274~0.6073
<0.0001
0.6478
0.4238~0.9903
0.0391
Radiotherapy
2.121
1.532~2.937
<0.0001
0.9892
0.5870~1.6670
0.9675
Risk score
4.172
3.503~4.969
<0.0001
1.7382
1.0577~2.8567
0.0292
Gender (female and male); Grade (WHO grade IV and III, II); IDH status (wildtype and mutant); Risk score (low and high); Chemotherapy (treated and untreated); Radiotherapy (treated and untreated). CI, confidence interval; HR, hazard ratio; IDH, isocitrate dehydrogenase.
